Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MTRAC reviews dementia drugs

The Midlands Therapeutics Review and Advisory Committee (MTRAC) has published reviews of the four drugs available for Alzheimer's disease.

The reviews of donepezil, galantamine, memantine and rivastigmine place all of the drugs as having a lower place in therapy with relatively weak evidence supporting use. Donepezil, galantamine and rivastigmine are suitable for prescribing in primary care provided that there is continued monitoring in secondary care or through shared care arrangements and treatment is stopped when appropriate as specified in the existing NICE Guidance. Memantine is classified as unsuitable for use in primary care.

Action: Clinicians will find these reviews contain a useful summary of the trial data for each drug. Throughout the trial data the reviews reveal small overall benefits, inconsistent results and use of subjective measures.

Share 'MTRAC reviews dementia drugs' on Email Share 'MTRAC reviews dementia drugs' on Delicious Share 'MTRAC reviews dementia drugs' on Digg Share 'MTRAC reviews dementia drugs' on Facebook Share 'MTRAC reviews dementia drugs' on Google+ Share 'MTRAC reviews dementia drugs' on reddit Share 'MTRAC reviews dementia drugs' on StumbleUpon Share 'MTRAC reviews dementia drugs' on Twitter

atomic-wealth

No Comments to “MTRAC reviews dementia drugs”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,520 spam comments.

atomic-wealth
fond-illness
summer